Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Recordati SpAMIL:REC +0.29%95 Days Sales Outstanding is 85.77 as of Jun. 2026, which is 29% above its 10-year median of 66.73. GuruFocus rates MIL:REC with a GF Score™ of 95/100 and a GF Value™ of €61.48 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 946 Drug Manufacturers companies, Recordati SpA ranks worse than 60.15% on this metric.
Recordati SpA's average Accounts Receivable for the
three
months ended in Jun. 2026 was €655 Mil. Recordati SpA's Revenue for the
three
months ended in Jun. 2026 was €697 Mil.
Hence, Recordati SpA's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 85.77.
The historical rank and industry rank for Recordati SpA's Days Sales Outstanding or its related term are showing as below:
MIL:REC'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 60.61 Med: 66.73 Max: 82.14
Current: 82.14
During the past 13 years, Recordati SpA's highest Days Sales Outstanding was 82.14. The lowest was 60.61. And the median was 66.73.
MIL:REC's Days Sales Outstanding is ranked worse than 60.15% of 946
companies
in the Drug Manufacturers industry
Industry Median: 71.925
vs MIL:REC: 82.14
Recordati SpA's Days Sales Outstanding
increased
from Jun. 2025 (84.51) to Jun. 2026 (85.77).
Recordati SpA (MIL:REC) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Recordati SpA Days Sales Outstanding Related Terms
Recordati SpA Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Recordati SpA's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:REC vs LLY, JNJ, ABBV: Days Sales Outstanding Comparison
For the Drug Manufacturers - General subindustry, Recordati SpA's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recordati SpA Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Recordati SpA's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Recordati SpA (MIL:REC) has a Days Sales Outstanding of 85.77 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Recordati SpA and its competitors. This is 29% above median its historical median of 66.73. Over the past decade, Recordati SpA's Days Sales Outstanding has ranged from 60.61 to 82.14. According to the industry distribution chart, Recordati SpA ranks #569 out of 946 companies in the Drug Manufacturers industry, placing it in the top 60.1%.
Is Recordati SpA's Days Sales Outstanding too high?
Recordati SpA's current Days Sales Outstanding of 85.77 is 29% above median its 10-year median of 66.73. Over the past 10 years, this metric has ranged from a low of 60.61 to a high of 82.14. The Drug Manufacturers industry median Days Sales Outstanding is 71.93. Recordati SpA's value of 85.77 is 19.2% above this industry median. Based on the distribution chart, Recordati SpA ranks #569 out of 946 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Recordati SpA has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recordati SpA's Days Sales Outstanding compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Recordati SpA ranks #569 out of 946 companies for Days Sales Outstanding. This places Recordati SpA in the lower half of its industry. The industry median Days Sales Outstanding is 71.93. Recordati SpA's value of 85.77 is 19.2% above this benchmark. Historically, Recordati SpA's own Days Sales Outstanding has ranged from 60.61 to 82.14 over the past decade. While the company's 10-year median is 66.73 vs. the industry median of 71.93, Recordati SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.93, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Recordati SpA's current Days Sales Outstanding of 85.77 is 19.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Recordati SpA and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Recordati SpA's current Days Sales Outstanding is 85.77, which is 29% above median its own 10-year median of 66.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recordati SpA stock overvalued right now?
Based on GuruFocus' analysis, Recordati SpA (MIL:REC) is currently considered Modestly Undervalued. The stock's GF Value™ is €61.48, compared to a current price of €51.95 — trading 15.5% below its estimated fair value. The current Days Sales Outstanding is 85.77, which is 29% above median its 10-year median of 66.73 and 19.2% above the Drug Manufacturers industry median of 71.93. Recordati SpA's overall GF Score™ is 95/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Recordati SpA (MIL:REC), the current Days Sales Outstanding is 85.77 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Recordati SpA (MIL:REC) Overvalued in 2026?
Based on GuruFocus' analysis, Recordati SpA stock appears to be undervalued.
The current stock price of €51.95 is trading 15.5% below its estimated GF Value™ of €61.48.
GuruFocus considers Recordati SpA to be Modestly Undervalued.
Key valuation signals for MIL:REC:
Days Sales Outstanding: 85.77 (29% above median its 10-year median of 66.73)
GF Value™: €61.48 vs. price of €51.95 (15.5% below fair value)
Industry Position: 19.2% above the Drug Manufacturers median (#569 of 946)
No single metric tells the full story. See the MIL:REC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical chemicals. The Company operates in a broad and diverse context, which includes general medicine, specialist medicine, self-medication, and rare diseases. In addition, it is also active in the field of urology, with treatments for benign prostatic hyperplasia and male functional disorders, and in psychiatry. The Company's only operating segment is the Specialty & Primary Care segment. Its geographic areas are Europe, Australasia, America, and Africa.
95GF Score
Get the complete analysis for MIL:REC
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:REC has been successfully added to your 
